Amanta Healthcare Files DRHP For IPO With Fresh Issue of 1.25 Cr Equity Shares

In order to be ready for the IPO, Amanta Healthcare Limited has submitted a draft red herring prospectus to the NSE and BSE. Up to 1,25,00,000 equity shares having a face value of Rs 10 apiece would be offered as a fresh issue. A maximum of 50% of the fresh issue will be set aside for eligible institutional buyers, 35% for retail investors, and 15% for non-institutional investors, as per the DRHP. According to the declaration, Link Intime India Pvt. will serve as the registrar and Beeline Capital Advisors Pvt. as the book-running lead manager for the Amanta Healthcare IPO. The company's promoters are Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendrakumar Patel, and Milcent Appliances Pvt.

Amanta Healthcare plans on spending Rs 70 crore of the net issue on equipment, plant, and machinery purchases as well as the necessary funding for civil construction work in order to establish a new SteriPort production line in Hariyala village of Kheda in Gujarat. The company also plans to invest Rs 30 crore from the new release on machinery, plant, and equipment to establish a new small-volume parenteral manufacturing line in Hariyala while the rest of the funds will be used for general corporate purposes. The objective of Amanta is to raise money for the capital expenditures necessary for civil construction projects as well as for the procurement of machinery, plant and equipment to establish a new SteriPort production line in Hariyala, Kheda, Gujarat. In addition, it seeks to acquire funds for general company objectives and the capital expenditures necessary to buy machinery, plant, and equipment for the establishment of a new Small Volume Parenteral (SVP) production line at the same site.

The firm recorded revenue of Rs 28,034.03 lakhs, EBITDA of Rs 5,875.65 lakhs, and PAT of Rs 363.32 lakhs for the quarter ending March 31, 2024. A pharmaceutical firm called Amanta Healthcare Limited focuses on creating, producing, and selling sterile liquid solutions. Amanta is engaged in providing drug absorption using parenteral solutions made with Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. Amanta produces medical devices and large and small-volume parenterals (LVPs and SVPs) for six therapeutic areas, including respiratory care, ophthalmics, and fluid treatment. With 113 current international product registrations, Amanta sells its products to 19 countries from its Gujarat plant.

Draft red herring prospectuses for Amanta Healthcare Ltd. and Chamunda Electrical Ltd.'s respective IPOs were submitted on Friday. Chamunda Electrical will be listed on the NSE Emerge platform, whereas Amanta Healthcare is a mainboard IPO and will be listed on the NSE and BSE. Through a fresh offering, Chamunda Electricals plans to issue up to 35 lakh shares. A maximum of 50% of the new issuance will be set aside for eligible institutional buyers, 35% for retail investors, and 15% for non-institutional investors, as per the DRHP. The registrar of the issuance will be KFin Technologies Ltd., while the book-running lead manager will be GYR Capital Advisors Pvt.